1. NYR is the very first of its kind in a new drug class 2. Small drug molecule and will have significantly be able to survive the bodies defence mechanisms compared to peptides in the brain. 3. The only drug in the world to target the 3 receptors in calcium influx which lead to secondary brain injury
That safety data is finisalising in coming days and together with the US ARMY pre clinical study. For a 9 million market cap, 6 million in the bank with additional non dilutive funding coming in on upcoming results, there is a significant amount of rerating coming up on clearing safety data and US Army success which then leads straight to injecting the first patient
NYR Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)